Clinical Trial Results of Pollogen's TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology
Posted on: Tuesday, 2 June 2009, 08:22 CDT
The study demonstrated long term measurable and durable body circumference and fat thickness reduction using objective measurement system (imaging Ultrasound). The study involved 37 patients treated once a week with the regen system for a total of eight treatments. Results showed that there was significant circumference reduction of 3.5 cm on average at the abdomen with a maximum of 14.4 cm, and 1.71 cm reduction at the thigh with a maximum of 9.1 cm. These results were maintained four weeks following the last treatment. In addition, ultrasound measurements of the distance between the epidermis and the superficial fascia showed an average reduction of 10.5% in the thickness of adipose tissue with a maximum reduction of 39% at the thigh region.
"TriPollar is a truly innovative technology that delivers what patients
worldwide have been waiting for- a pain free, safe and effective solution for
body contouring. The latest study clearly demonstrated that TriPollar RF
technology provides beneficial effects on the reduction of abdomen and thigh
circumferences and an overall improvement in the appearance of cellulite."
said Dr. Manuskiatti, lead investigator for Pollogen's clinical trial and
Associate Professor at the Department of Dermatology at the Siniraj Hospital,
Ms.
About Pollogen:
Pollogen Ltd. develops, manufactures and markets professional medical aesthetic devices, powered by the TriPollar(TM) 3rd generation Radio Frequency (RF) technology. Invented and perfected by Pollogen, proprietary TriPollar(TM) technology powers a full line of clinically-proven, non-invasive and non-surgical treatment platforms for wrinkles, cellulite, circumference reduction and skin tightening. The flagship aesthetic devices, apollo(TM) and regen(TM) offer customers clinically-proven, safe and effective anti-aging beauty treatments that deliver immediate and long-lasting results. To learn more, please visit the Pollogen website at http://www.pollogen.com
Contact: Name: Abigail Marks Tel: +972-54-244-5807 E-mail: abigail_m@pollogen.comSOURCE Pollogen Ltd
Source: PR Newswire
Related Articles
- Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
- Study Finds More Effective Treatment for Pneumonia Following Influenza
- New CHARISMA Outcome Study Results Validate Aspirin Effect
- Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
- SAVI Device for Treatment of Breast Cancer Shows Excellent Cosmetic Results, Few Side Effects
- Repros' IND for the Commencement of Phase III Studies of Proellex(R) in the Treatment of Anemia Associated With Uterine Fibroids is Now Effective
- MediciNova Reports Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia
- Results From a Cost-Effectiveness Study Demonstrate Positive Economic Impact With PEGASYS(R) Treatment
- Research Across America Announces Methamphetamine Addiction Treatment Protocol Study Results; More Than 80% of Study Participants Experienced Significant Clinical Benefit
- New Study Results Demonstrate Clinical Effectiveness of Gemzar(R)-Based Combination Therapy for Advanced Breast Cancer
User Comments (0)

RSS Feeds